Circulating Mitochondrial Biomarkers Show Promise for Acute Heart Attack Diagnosis

Acute Coronary Syndrome (ACS), encompassing conditions like heart attack, remains a leading cause of mortality, requiring rapid and accurate diagnosis for effective treatment. Current diagnostic methods, primarily based on symptoms, ECG changes, and cardiac troponin levels, can sometimes be delayed or lack specificity in early stages. This study addresses the critical need for novel, non-invasive biomarkers that can provide earlier and more precise detection of myocardial injury in ACS.

The study identified significant alterations in circulating mitochondrial biomarkers in patients with Acute Coronary Syndrome. Levels of mtDNA (mitochondrial DNA) were found to be markedly elevated in ACS patients compared to healthy controls, suggesting substantial mitochondrial damage during cardiac events. Similarly, TFAM (mitochondrial transcription factor A) levels also showed a significant increase, correlating with the extent of myocardial injury. The study demonstrated that specific circulating mitochondrial biomarkers, including mtDNA and TFAM, are significantly elevated in Acute Coronary Syndrome patients, indicating their strong potential as novel diagnostic indicators. Furthermore, these biomarkers exhibited a strong correlation with traditional markers of cardiac damage and adverse clinical outcomes, suggesting their utility in risk stratification. The findings indicate that these mitochondrial components are released into circulation following acute myocardial ischemia.